We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -6.06% | 1.55 | 1.50 | 1.60 | 1.65 | 1.475 | 1.65 | 8,522,072 | 16:15:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.30 | 12.02M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/3/2021 22:14 | $200k per rep per year fully loaded, so team of 60 field-based staff = $12m per year. Add in office-based staff,manufacturing costs (handled via transfer pricing with UK parent), promotional costs etc... and you get to their cost forecast. Simply put... early revenues and listing by major US private payors absolutely key as those things will engender confidence, bring in US investors, allow reasonably priced further fund raising if required and perhaps even lead to a joint listing (& associated valuation rerating) on NASDAQ. Fingers crossed. | innittowinit | |
09/3/2021 17:37 | Did he say SG&A $45M pa in 2-3 years? I reckon 60reps c$5m the big cost i would think so where does $45M come from? If it accelerates to anywhere near that it spells trouble | powerp2 | |
09/3/2021 17:14 | @ power That was me..."Mr Groch. In 4 of your last 5 jobs you lasted approximately a year. Should we be worried about your longevity?" | t0pgrader | |
09/3/2021 17:13 | I suggested that before but he ignored it When TW asked how long is left (no clock on his laptop !?!?!) he might just as well have said wrap this up and bale me out please | powerp2 | |
09/3/2021 17:10 | From the detailed market Research opportunity in the states which if you believe looks substantial with great pricing power why in 18 months couldn’t they get a licensing deal done it’s a real mystery. But I liked Brian he obviously knows the market place extremely well and if they deliver as planned then today’s valuation is a giveaway | best1467 | |
09/3/2021 17:06 | Yes, launch in US, and he says sometime Q2, probably late (groan). Just give the month ! Could AZN snap them up to go alongside their product I wonder .... | daveboy19 | |
09/3/2021 17:06 | Someone touched a nerve with BG let's hope he proves them wrong! | powerp2 | |
09/3/2021 17:03 | I like straight talk and a clear business plan with measurable and timelines - this was missing. The "launch plan" on page 21 is a generic slide for launching a pharmacy product - where was the timings? I'dlike to see a detailed cash flow forecast as if we don't see revenues fast 're cash burn will hit even harder and we'll run out again | powerp2 | |
09/3/2021 16:46 | Our CEO is a truly dire presenter. Awful | toffeeman | |
09/3/2021 16:11 | As usual, hissing the time away, when we all want to talk route to market. FFS. | daveboy19 | |
09/3/2021 12:14 | Still think better entry after Agm when placees will dump | nico115 | |
09/3/2021 09:21 | Too true, powerp2. Let's hope they get onto Brian asap, and he has plenty of drive to recharge this beast. | daveboy19 | |
09/3/2021 09:16 | Anyone know the actual number of patients each month and the actual value of sales in each territory? Would be great to know these stats to work out the speed of the roll out. With huge margins getting traction on the volumes is critical to profits. | sharpshare | |
09/3/2021 09:06 | I agree Daveboy19. It might also encourage a more balanced approach to the placing price. The timing of news I believe is manipulated but not only by Shield it is widespresd. Then of course what is news? Directors no doubt would argue about its materiality. Bottom line for me is as much timely transparency as possible. I wonder if TW tries to dine out on this today. I want to hear about a robust US plan with key milestones identified for review and not flannel | powerp2 | |
09/3/2021 08:44 | Surely news cannot be withheld and released as and when the company chooses, but only when it is known... Should put a 180 day clause on sale of placing shares to properly support the company going forward and not just flip an easy profit to it's detriment. | daveboy19 | |
09/3/2021 08:22 | Wouldn't it better to release these sorts of news after placing shares have hit the market as any rise may get sold into due to the price being at premium now | 78steve | |
09/3/2021 07:37 | The Cap here is ridiculous. Take advantage of it. Load up if you can. | hodhasharon | |
09/3/2021 07:23 | Good news !! Simple .. just buy back in pal ! | amaretto1 | |
09/3/2021 07:22 | Stage managed or not it’s still a further territory to grow sales | best1467 | |
09/3/2021 07:16 | All very stage managed! It's substance i want to see in top line revenue hopefully he'll tell us of a licensing sggreement to be signed there with a partner who will deliver and a decent down payment | powerp2 | |
09/3/2021 07:13 | Nice unexpected news for a change let’s see an impressive detailed confident presentation from Groch and hopefully the tide is beginning to turn | best1467 | |
09/3/2021 07:03 | Aussies r with us !! Onwards and upwards :-) | amaretto1 | |
08/3/2021 17:09 | Big trades at the end. Someone else is buying. Heading back up? | frrinvest | |
08/3/2021 14:59 | Powerp, you might point out to them that Watts is one of the worst presenters they have ever given air time to, and that we really want to hear from Groch... | waggle | |
08/3/2021 14:50 | Powerp2 I second that but I suspect they won't take up your suggestion. | frrinvest |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions